{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:59:22Z","timestamp":1785337162896,"version":"3.55.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold>Mortality associated with invasive group A streptococcal infections (iGAS) remains high among adults, with lower mortality in children. The added value of both clindamycin and immunoglobulins in such treatment is still controversial, as is the need for antibiotic secondary prophylaxis. It is unlikely that conclusive randomized clinical studies will ever definitively end these controversies.<\/jats:p><jats:p><jats:bold>Materials and Methods:<\/jats:bold>A clinical and experimental literature review was conducted in Pubmed, Cochrane, and lay literature to determine the benefit of adding clindamycin and immunoglobulins to \u03b2-lactams in the management of iGAS, as well as the need for secondary prophylaxis measures in close contacts.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>This review includes two meta-analyses, two randomized controlled trials, four prospective studies, five retrospective studies, and microbiological studies. To reduce mortality and morbidity, it appears useful to add clindamycin to \u03b2-lactams in severe clinical presentations, including necrotizing fasciitis or streptococcal toxic shock syndrome, and immunoglobulins for the latter two presentations. The high risk of secondary infection in household contacts justifies the need of taking preventive measures.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold>Both clinical studies and available experimental evidence suggest that adding clindamycin and immunoglobulins as adjunctive therapies in the management of invasive group A streptococcal infections may reduce mortality. Household contacts should be warned about the increased risk of secondary infection, and chemoprophylaxis may be considered in certain situations.<\/jats:p>","DOI":"10.3389\/fped.2021.697938","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T14:01:00Z","timestamp":1629468060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Invasive Group A Streptococcal Infections: Benefit of Clindamycin, Intravenous Immunoglobulins and Secondary Prophylaxis"],"prefix":"10.3389","volume":"9","author":[{"given":"Delphine","family":"Laho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Blumental","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Botteaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre R.","family":"Smeesters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2165\/11634180\u2013000000000-00000","article-title":"Invasive group a streptococcal disease: epidemiology, pathogenesis and management","volume":"72","author":"Steer","year":"2012","journal-title":"Drugs."},{"key":"B2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/cid\/ciz1000","article-title":"Streptococcus pyogenes pbp2x mutation confers reduced susceptibility to \u03b2-Lactam antibiotics","volume":"71","author":"Vannice","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1086\/521264","article-title":"The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004","volume":"45","author":"O'Loughlin","year":"2007","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.molmed.2013.10.004","article-title":"Streptococcal superantigens: categorization and clinical associations","volume":"20","author":"Commons","year":"2014","journal-title":"Trends Mol Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/QCO.0000000000000452","article-title":"Group A Streptococcus infections in children: from virulence to clinical management","volume":"31","author":"Botteaux","year":"2018","journal-title":"Curr Opin Infect Dis."},{"key":"B7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-030-57616-5_10","article-title":"Systems genetics approaches in mouse models of group a streptococcal necrotizing soft-tissue infections","volume-title":"Necrotizing Soft Tissue Infect Clin Pathog Asp","author":"Nookala","year":"2020"},{"key":"B8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1099\/mic.0.000612","article-title":"The DNases of pathogenic Lancefield streptococci","volume":"164","author":"Remmington","year":"2018","journal-title":"Microbiology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1016\/S0163-4453(17)30206-2","article-title":"Toxic shock syndrome \u2013 the seven Rs of management and treatment","volume":"74","author":"Wilkins","year":"2017","journal-title":"J Infect."},{"key":"B10","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1086\/342692","article-title":"Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention","volume":"35","year":"2002","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B11","volume-title":"Public Health Management of Invasive Group A Streptococcal Infection","year":"2015"},{"key":"B12","unstructured":"Interim UK guidelines for management of close community contacts of invasive group A streptococcal disease35461Commun Dis Public Health72004"},{"key":"B13","volume-title":"Avis relatif \u00e0 la conduite \u00e0 tenir autour d'un ou de plusieurs cas, d'origine communautaire, d'infections invasives \u00e0 Streptococcus pyogenes (ou streptocoques du groupe A) s\u00e9ance du 18 Novembre","year":"2005"},{"key":"B14","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1542\/9781581109276-Group","volume-title":"Red Book: 2015 Report of the Committee on Infectious Diseases","author":"Kimberlin","year":"2015"},{"key":"B15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/pch\/pxz039","article-title":"Invasive group A streptococcal disease: Management and chemoprophylaxis","volume":"24","author":"Moore","year":"2019","journal-title":"Paediatr Child Health."},{"key":"B16","volume-title":"The Managment of Invasive Group A Streptococcal Infections in Ireland. Invasive group A streptococcus Sub-Committee","year":"2006"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/S0929-693X(14)72267-5","article-title":"[Management of severe invasive group A streptococcal infections]","volume":"21","author":"Faye","year":"2014","journal-title":"Arch Pediatr Organe Off Soc Francaise Pediatr."},{"key":"B18","unstructured":"Groep A Streptokokkeninfecties: Roodvonk, Krentenbaard, Acuut Reuma, Invasieve Infectie. [Internet]2016"},{"key":"B19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/cid\/ciu304","article-title":"Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections","volume":"59","author":"Carapetis","year":"2014","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/infdis\/jiu091","article-title":"Increased neutrophil extracellular trap-mediated Staphylococcus aureus clearance through inhibition of nuclease activity by clindamycin and immunoglobulin","volume":"210","author":"Schilcher","year":"2014","journal-title":"J Infect Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/cid\/ciu449","article-title":"Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study","volume":"59","author":"Linn\u00e9r","year":"2014","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jac\/dkl173","article-title":"Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation","volume":"58","author":"Sriskandan","year":"2006","journal-title":"J Antimicrob Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"15825","DOI":"10.1038\/srep15825","article-title":"Identification of the Streptococcus pyogenes surface antigens recognised by pooled human immunoglobulin","volume":"5","author":"Reglinski","year":"2015","journal-title":"Sci Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cmi.2018.07.007","article-title":"Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model","volume":"25","author":"Tarnutzer","year":"2019","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis."},{"key":"B25","first-page":"3057","article-title":"Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production","volume":"156","author":"Norrby-Teglund","year":"1996","journal-title":"J Immunol Baltim Md."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/cid\/ciaa022","article-title":"Correlation between immunoglobulin dose administered and plasma neutralization of streptococcal superantigens in patients with necrotizing soft tissue infections","volume":"71","author":"Bergsten","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1086\/515199","article-title":"Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome\u2013a comparative observational study. The Canadian Streptococcal Study Group","volume":"28","author":"Kaul","year":"1999","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1086\/376630","article-title":"Intravenous immunoglobulin G therapy in Streptococcal toxic shock syndrome: a european randomized, double-blind, placebo-controlled trial","volume":"37","author":"Darenberg","year":"2003","journal-title":"Clin Infect Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/cid\/ciw871","article-title":"Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity score\u2013matched analysis from 130 US hospitals","volume":"64","author":"Kadri","year":"2017","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00134-017-4786-0","article-title":"Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial","volume":"43","author":"Madsen","year":"2017","journal-title":"Intensive Care Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1086\/606048","article-title":"Intravenous immunoglobulin in children with streptococcal toxic shock syndrome","volume":"49","author":"Shah","year":"2009","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/archdischild-2013-304741","article-title":"In association with the British Paediatric Surveillance Unit. Toxic shock syndrome surveillance in UK children","volume":"99","author":"Adalat","year":"2014","journal-title":"Arch Dis Child"},{"key":"B33","doi-asserted-by":"publisher","first-page":"CD001090","DOI":"10.1002\/14651858.CD001090.pub2","article-title":"Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock","volume":"2013","author":"Alejandria","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1093\/cid\/ciy401","article-title":"Polyspecific intravenous immunoglobulin in clindamycin-treated patients with Streptococcal toxic shock syndrome: a systematic review and meta-analysis","volume":"67","author":"Parks","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/00006454-199912000-00014","article-title":"Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection","volume":"18","author":"Zimbelman","year":"1999","journal-title":"Pediatr Infect Dis J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1097\/01.SMJ.0000051060.95210.9A","article-title":"Invasive group A streptococcal infections in Florida","volume":"96","author":"Mulla","year":"2003","journal-title":"South Med J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1473-3099(20)30523-5","article-title":"Effectiveness of adjunctive clindamycin in \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study","volume":"21","author":"Babiker","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"B38","unstructured":""},{"key":"B39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0002-9343(52)90293-3","article-title":"Experimental approach to the problem of treatment failure with penicillin","volume":"13","author":"Eagle","year":"1952","journal-title":"I. Group A streptococcal infection in mice. Am J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/158.1.23","article-title":"The eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis","volume":"158","author":"Stevens","year":"1988","journal-title":"J Infect Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/jac\/40.2.275","article-title":"Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes","volume":"40","author":"Sriskandan","year":"1997","journal-title":"J Antimicrob Chemother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/infdis\/jiw229","article-title":"Clindamycin affects Group A Streptococcus virulence factors and improves clinical outcome","volume":"215","author":"Andreoni","year":"2017","journal-title":"J Infect Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/archdischild-2015-309788","article-title":"QUESTION 1: are household contacts of patients with invasive group A streptococcal disease at higher risk of secondary infection?","volume":"101","author":"Carr","year":"2016","journal-title":"Arch Dis Child."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3201\/eid2510.181408","article-title":"Risk for invasive streptococcal infections among adults experiencing homelessness, Anchorage, Alaska, USA, 2002\u20132015","volume":"25","author":"Mosites","year":"2019","journal-title":"Emerg Infect Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/cid\/ciy429","article-title":"Risk factors for Group A Streptococcus colonization during an outbreak among people experiencing homelessness in Anchorage, Alaska, 2017","volume":"67","author":"Adebanjo","year":"2018","journal-title":"Clin Infect Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/jpc.12659","article-title":"Invasive group A streptococcal infection in the Northern Territory, Australia: case report and review of the literature","volume":"50","author":"Middleton","year":"2014","journal-title":"J Paediatr Child Health."},{"key":"B47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1056\/NEJM199608223350803","article-title":"Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group","volume":"335","author":"Davies","year":"1996","journal-title":"N Engl J Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/cid\/ciu752","article-title":"Global assessment of invasive group a streptococcus infection risk in household contacts","volume":"60","author":"Lamagni","year":"2015","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3201\/eid0904.020369","article-title":"Risk for severe Group A Streptococcal disease among patients' household contacts","volume":"9","author":"Robinson","year":"2003","journal-title":"Emerg Infect Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"30532","DOI":"10.2807\/1560-7917.ES.2017.22.19.30532","article-title":"Household transmission of invasive group A Streptococcus infections in England: a population-based study, 2009. 2011 to 2013","volume":"22","author":"Mearkle","year":"2017","journal-title":"Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull"},{"key":"B51","doi-asserted-by":"publisher","first-page":"CD004785","DOI":"10.1002\/14651858.CD004785.pub5","article-title":"Antibiotics for preventing meningococcal infections","volume":"2013","author":"Zalmanovici Trestioreanu","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"B52","unstructured":"LondonRCOG PressBacterial Meningitis and Meningococcal Septicaemia: Management of Bacterial Meningitis and Meningococcal Septicaemia in Children and Young People Younger than 16 Years in Primary and Secondary Care [Internet]2010"},{"key":"B53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0022-3476(85)80687-9","article-title":"Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: a randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final 4 days of therapy","volume":"106","author":"Chaudhary","year":"1985","journal-title":"J Pediatr."},{"key":"B54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0022-3476(05)81052-2","article-title":"Clindamycin treatment of chronic pharyngeal carriage of group A streptococci","volume":"119","author":"Tanz","year":"1991","journal-title":"J Pediatr."},{"key":"B55","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1542\/peds.113.4.866","article-title":"Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children","volume":"113","author":"Casey","year":"2004","journal-title":"Pediatrics."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1086\/392496","article-title":"Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults","volume":"38","author":"Casey","year":"2004","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B57","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1473-3099(05)70190-0","article-title":"Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis?","volume":"5","author":"Smith","year":"2005","journal-title":"Lancet Infect Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jpids\/piu107","article-title":"Management of contacts of patients with severe invasive group a streptococcal infection","volume":"5","author":"de Almeida Torres","year":"2016","journal-title":"J Pediatr Infect Dis Soc."},{"key":"B59","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0140-6736(07)60235-9","article-title":"Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study","volume":"369","author":"Malhotra-Kumar","year":"2007","journal-title":"Lancet Lond Engl."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.697938\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T19:10:58Z","timestamp":1673118658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.697938\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":59,"alternative-id":["10.3389\/fped.2021.697938"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.697938","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"article-number":"697938"}}